Trials / Completed
CompletedNCT00665106
Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of NOVA63035 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Santen SAS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NOVA63035 "Corticosteroid" | Single injection in the study eye |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2008-04-23
- Last updated
- 2015-05-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00665106. Inclusion in this directory is not an endorsement.